We Invest Early
Acquiring Drug Assets, Not Companies
We source drug assets in the early stages of preclinical and clinical development, and assume full responsibility for value creation through further development. We have expertise in small molecules as well as biologics across most therapeutic areas, and prefer to acquire drug assets in early stages of clinical development in order to advance them to proof-of-concept and exit.
Investing early combined with our de-risking capabilities creates the opportunity for superior returns earlier.